Aclarion (NASDAQ:ACON) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Aclarion (NASDAQ:ACON) from a sell rating to a hold rating in a report issued on Saturday morning.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Aclarion in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Aclarion Price Performance

NASDAQ ACON opened at $3.08 on Friday. Aclarion has a 12 month low of $2.34 and a 12 month high of $13.69. The firm has a market capitalization of $7.02 million, a PE ratio of -0.18 and a beta of 1.44. The company’s 50 day simple moving average is $3.06 and its 200 day simple moving average is $5.47.

Aclarion (NASDAQ:ACON) last released its earnings results on Wednesday, March 18th. The company reported ($2.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.60) by $1.59. The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.02 million. Aclarion had a negative return on equity of 52.31% and a negative net margin of 9,517.11%. Sell-side analysts anticipate that Aclarion will post -263.33 earnings per share for the current fiscal year.

About Aclarion

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.